



## Direct Healthcare Professional Communication (DHPC)

**Date: 19 Nov 2025**

**Subject: Important Safety Information Regarding Yescarta® (axicabtagene ciloleucel) and Risk of Cerebral Edema in Primary Mediastinal B Cell Lymphoma (PMBCL)**

**Dear Health Care Provider,**

The marketing authorisation holder (MAH) Gilead Sciences Ireland UC, (hereafter referred to as Gilead), in agreement with the Saudi Food and Drug Authority (SFDA), would like to inform you of important safety information regarding the possible risk of cerebral edema, which may progress rapidly with potentially fatal outcomes in patients with primary mediastinal B cell lymphoma (PMBCL) treated with Yescarta® (axicabtagene ciloleucel). Cerebral edema is a known risk of CAR-T therapy and is described in the Yescarta Prescribing Information.

### **Risk of Cerebral Edema:**

- Patients with PMBCL may be at increased risk for developing cerebral edema, which can be fatal. The underlying mechanism of this risk is not known and may involve disease biology, anatomical location (large mediastinal mass), prior therapy, and/or other factors.
- The cerebral edema reporting rate to Gilead/Kite in PMBCL is 1.4% (0.9% fatal) compared with 0.2% (0.1% fatal) in Diffuse Large B Cell Lymphoma (DLBCL). The cerebral edema reporting rate in US and EU patient registry studies was consistent at 1.7% (0.8% fatal) in PMBCL and 0.7% (0.2% fatal) in DLBCL.
- Cerebral edema may evolve as a manifestation of Immune-Effector Cell Associated Neurotoxicity Syndrome (ICANS) but does not follow a predictable clinical course and in some cases has occurred after only mild neurologic symptoms.
- The etiology of cerebral edema, independent of CAR-T therapy, is not fully understood; risk factors include and are not limited to: Superior vena cava (SVC) syndrome, sepsis or other systemic infections, kidney disease, hyponatremia, and brain radiation therapy.

### **Prescriber Action:**

- Consider increasing the frequency of monitoring for ICANS in PMBCL patients during the first 7-14 days of Yescarta therapy, because cerebral edema can develop rapidly following mild neurological symptoms.
- Promptly initiate treatment for ICANS per applicable guidelines. Initiate prompt evaluation (e.g., neuroimaging) and consultation (e.g., neurosurgery) if cerebral edema is suspected.
- Published case reports have suggested intrathecal therapy may be useful for the management of ICANS (see references). Clinical status and contraindications for lumbar puncture should be appropriately considered.

### **Reporting Adverse Events:**

Health care providers and patients are encouraged to report adverse events in patients taking Yescarta to Kite at [Drugsafety.KSA@gilead.com](mailto:Drugsafety.KSA@gilead.com). You are encouraged to report negative side effects of prescription drugs to the National Pharmacovigilance Centre (NPC) unified number: 19999 or email: [npc.drug@sFDA.gov.sa](mailto:npc.drug@sFDA.gov.sa).

You may also contact our medical information department at [askgileadME@gilead.com](mailto:askgileadME@gilead.com) if you have any questions about the information contained in this letter or the safe and effective use of Yescarta. This letter is not intended as a complete description of the benefits and risks related to the use of Yescarta. Please refer to the full prescribing information enclosed.

**Yours faithfully,**

Mohannad Alghamdi  
Head of Patient Safety & QPPV of Gilead/Kite

Signed by Mohannad Alghamdi



*Mohannad Alghamdi* | I approve this document  
November 19, 2025 | 8:25:53 AM PST

1E9F7E4730364D35AE93A026222E951C

### **References**

#### **Cerebral edema risk and management**

Liotta EM. Management of Cerebral Edema, Brain Compression, and Intracranial Pressure. Continuum (Minneapolis) 2021;27 (5):1172-200.

Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. The New England journal of medicine 2007;356 (18):1862-9.

Chow R, Simone CB, 2nd, Rimner A. Management of malignant superior vena cava syndrome. Ann Palliat Med 2024;13 (3):620-6.

Sonneville R, Benghanem S, Jeantin L, de Montmollin E, Doman M, Gaudemer A, et al. The spectrum of sepsis-associated encephalopathy: a clinical perspective. Crit Care 2023;27 (1):386.

Adrogué HJ, Madias NE. Hyponatremia. The New England journal of medicine 2000;342 (21):1581-9.

Arnold R, Issar T, Krishnan AV, Pussell BA. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis 2016;5

Turnquist C, Harris BT, Harris CC. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neurooncol Adv 2020;2 (1):vdaa057.

Miller Fisher, C. Brain Herniation: A Revision of Classical Concepts Can. J. Neurol. Sci. 1995; 22: 83-911.

### **Intrathecal Therapy for ICANS**

Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv 2020; 4 (10): 2119–2122.

Zurko JC, Johnson BD, Aschenbrenner E, et al. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022;8(5):773–775.

Bashey SZ, Solomon SR, Zhang X, Morris LE, Holland HK, Bachier L, Patel K, Solh MM. Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity. Bone Marrow Transplant. 2024 Dec;59(12):1783-1785.

Akhom, PA, Johnson G, Hoeyneck B, ... Jayani RV, Oluwale OO, Kassim AA. The Safety of Intrathecal Therapy in the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Transplantation and Cellular Therapy, 2025 Volume 31, Issue 2, S239